<DOC>
	<DOCNO>NCT00389181</DOCNO>
	<brief_summary>The purpose study determine medical management well invasive therapy improve long-term outcome patient unruptured brain arteriovenous malformation .</brief_summary>
	<brief_title>A Randomized Trial Unruptured Brain AVMs</brief_title>
	<detailed_description>Brain arteriovenous malformation ( BAVMs ) infrequent important cause stroke , particularly young population . Current invasive treatment strategy vary include endovascular procedure , neurosurgery , radiotherapy . All treatment administer assumption achieve acceptably minor complication rate , decrease risk subsequent hemorrhage , lead well long-term outcome . Recent data literature compare initial presentation outcome patient rupture unruptured BAVMs raise possibility elective invasive treatment unruptured BAVMs may yield bad outcome manage patient symptomatically therapy . Unfortunately , control clinical trial yet undertaken management unruptured BAVMs address concern . Therefore , goal randomize control trial determine long-term outcome patient receive medical management symptom ( e.g. , headache , seizure ) associate unruptured BAVM superior receive medical management invasive therapy eradicate BAVM . Participants randomly assign receive either symptomatic medical management alone management invasive therapy ( combination surgery , endovascular embolization , radiotherapy ) . Functional assessment carry time randomization , pre-intervention 48-hour post-intervention , participant 1 month , 6 month interval throughout follow period minimum 5 year .</detailed_description>
	<mesh_term>Congenital Abnormalities</mesh_term>
	<mesh_term>Arteriovenous Malformations</mesh_term>
	<mesh_term>Hemangioma</mesh_term>
	<mesh_term>Intracranial Arteriovenous Malformations</mesh_term>
	<criteria>1 . Patient must unruptured BAVM diagnosed MRI/MRA , CTA and/or angiogram 2 . Patient must 18 year age old 3 . Patient must sign Informed Consent , Release Medical Information , Health Insurance Portability Accountability Act ( HIPAA/U.S . ) Forms 1 . Patient BAVM presenting evidence recent prior hemorrhage 2 . Patient receive prior BAVM therapy ( endovascular , surgical , radiotherapy ) 3 . Patient BAVM deem untreatable local team , concomitant vascular brain disease interfere with/or contraindicates interventional therapy type ( stenosis/occlusion neck artery , prior brain surgery/radiation reason ) 4 . Patient baseline Rankin ≥2 5 . Patient concomitant disease reduce life expectancy le 10 year 6 . Patient thrombocytopenia ( &lt; 100,000/μL ) , 7 . Patient uncorrectable coagulopathy ( INR &gt; 1.5 ) 8 . Patient pregnant lactate 9 . Patient know allergy iodine contrast agent 10 . Patient multiplefoci BAVMs 11 . Patient form arteriovenous spinal fistula Previous diagnosis follow 12 . Patient diagnose Vein Galen type malformation 13 . Patient diagnose cavernous malformation 14 . Patient diagnose dural arteriovenous fistula 15 . Patient diagnose venous malformation 16 . Patient diagnose neurocutaneous syndrome cerebroretinal angiomatosis ( von HippelLindau ) , encephalotrigeminal syndrome ( SturgeWeber ) , WyburnMason syndrome 17 . Patient diagnose BAVMs context moyamoyatype change 18 . Patient diagnose hereditary hemorrhagic telangiectasia ( RenduOslerWeber )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2015</verification_date>
	<keyword>Unruptured brain arteriovenous malformation</keyword>
	<keyword>AVM</keyword>
	<keyword>BAVM</keyword>
	<keyword>Stroke</keyword>
	<keyword>Intracranial Hemorrhage</keyword>
</DOC>